Clinical Evolution in Patients With New-Onset Inflammatory Back Pain: A Population-Based Cohort Study.

Runsheng Wang Cynthia S CrowsonKerry WrightMichael M Ward

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2018)

In a minority of patients, new-onset IBP progresses to SpA, while IBP resolves in many. That IBP often resolves may explain the difference between the prevalence of IBP (3-6%) and the prevalence of SpA (0.4-1.3%).

Keyphrases

end stage renal disease
risk factors
ejection fraction
newly diagnosed
chronic kidney disease
oxidative stress
patient reported outcomes